MHRA issues a summary of advice on the use of NRT

Following the introduction of smoke-free legislation in England preventing smoking in enclosed public places, the MHRA has issued a summary of information relating to nicotine replacement therapy (NRT).

The advice covers the main differences between the available NRT preparations (chewing gum, patches, tablets, lozenges, inhalators and nasal sprays), and reiterates advice issued by the Committee on Safety of Medicines in December 2005, on the safe use of NRT in at-risk populations, including:

  • Adolescents aged 12 years and over.
  • Pregnant or breast-feeding women.
  • Smokers with underlying disease such as cardiovascular, hepatic or renal impairment.
  • Diabetes.
  • Those taking concurrent medication.

Further information at

The MIMS patient factsheet on smoking cessation has also been updated recently. It covers the different types of NRT and inludes information on the prescription medicines Champix (varenicline) and Zyban (bupropion). Smoking cessation services are included in the self-help directory.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Follow Us: